Redhill Biopharma Ltd. RDHL

RedHill Biopharma acquires Rebyota and Clenpiq commercialization rights for $12M upfront plus royalties, expanding its gastrointestinal portfolio with potential sales growth questions. Acquisition adds new marketed products and represents major strategic expansion of RedHill's commercial operations.

RedHill Biopharma acquires commercialization rights to Ferring's Rebyota and Clenpiq in a transformational deal expanding its product portfolio. Acquisition of Rebyota and Clenpiq rights fundamentally expands RedHill's commercial operations and revenue base.

RedHill Biopharma acquires commercialization rights to Ferring’s Rebyota® for recurrent C. difficile infection and Clenpiq® for bowel preparation, adding immediate revenue-generating assets and expanding its U.S. commercial footprint. Acquisition delivers two marketed products and revenue streams that materially strengthen RDHL's commercial operations and growth trajectory.

Redhill Biopharma Ltd. (RDHL) stock doubled in one trading session. Stock doubling signals major positive development likely to alter company trajectory and investor sentiment.

RedHill Biopharma divests Talicia to Apotex for $18 million cash upfront plus milestones to fund strategic growth opportunities. Divestiture injects immediate capital and milestones to redirect RedHill toward new strategic initiatives.

Ebola cases and deaths are surging rapidly. RedHill Biopharma updates on Opaganib development for emergency outbreak use. Opaganib positioning for Ebola outbreak response signals major strategic and market upside for RedHill Biopharma.

RedHill Biopharma Ltd. closes private placement raising up to $19.4 million. Private placement supplies RedHill Biopharma with capital that can support operations without fundamentally shifting company trajectory.

RedHill Biopharma secures up to $19.4 million via private placement to support operations. Capital infusion improves near-term financial runway but triggers dilution without altering core pipeline outlook.

RedHill's Opaganib receives FDA Rare Pediatric Disease Designation for Neuroblastoma, adding to its existing Orphan Drug Designation. FDA designation grants incentives for Opaganib in neuroblastoma but remains an early regulatory step without immediate commercial impact.

RedHill Biopharma advances opaganib options as dual host-directed and direct-acting antiviral for Ebola outbreak biodefense platforms. Opaganib Ebola biodefense advancement opens major new market and contract opportunities for RDHL.

RedHill Biopharma's RHB-204 demonstrates MAP-killing efficacy comparable to RHB-104, marking an important advancement in its development for MAP-related Crohn's Disease. Comparable efficacy data advances RHB-204 development, moderately boosting RDHL's pipeline prospects for Crohn's treatment.

RedHill Biopharma Ltd. (RDHL) announced full-year 2025 financial results and operational highlights. Full-year financial results and operational highlights represent major disclosures that can significantly sway investor sentiment and stock trajectory.

RedHill Biopharma presented preclinical data at AACR 2026 showing opaganib enhances efficacy of neuroblastoma chemotherapy combinations and augments anti-tumor immunity in triple-negative breast cancer. Preclinical results expand opaganib's potential indications in neuroblastoma and triple-negative breast cancer, offering moderate boost to pipeline prospects and market sentiment.

Cumberland Pharmaceuticals launches U.S. promotion of Talicia, Redhill Biopharma's FDA-approved first-line therapy for Helicobacter pylori (H. pylori) infection, under their exclusive commercialization agreement. Cumberland's U.S. promotion launch of Talicia activates key commercialization milestones and royalty payments for Redhill Biopharma.

RedHill Biopharma Ltd. (RDHL) and its commercialization partner have commenced joint U.S. launch of Talicia®, the first FDA-approved therapy with new mechanism for H. pylori eradication, targeting a high unmet need in a large market. Joint U.S. commercialization launch of Talicia® opens substantial revenue potential and validates RedHill's key asset in a major market.

RedHill Biopharma Ltd. announced progress in its RHB-102 program, targeting multiple gastrointestinal (GI) indications, including addressing GI side effects related to GLP-1 therapy. The company is advancing its clinical trials and aims to provide solutions for patients experiencing these adverse effects, potentially enhancing treatment options in the GI space. Advancements in RHB-102 could significantly impact RedHill's market position and investor sentiment in the GI therapeutic area.

RedHill Biopharma Ltd. announced positive results from its study on opaganib, indicating a reduction in venetoclax-resistant cells. This finding suggests potential advancements in treating certain types of cancer, particularly in patients who have developed resistance to existing therapies. The results may enhance the company's position in the oncology market and support further development of opaganib as a treatment option. The positive results from the opaganib study could significantly impact RedHill Biopharma's future performance and market positioning in oncology.

RedHill Biopharma Ltd. has successfully regained compliance with Nasdaq's stockholders' equity requirement, following a series of strategic financial maneuvers. The company had previously faced challenges in meeting the minimum equity threshold but has now taken necessary actions to align with Nasdaq's regulations. This compliance is crucial for maintaining its listing on the exchange and supports RedHill's ongoing efforts to enhance its market position and investor confidence. Regaining compliance with Nasdaq's requirements significantly impacts the company's market standing and investor sentiment.

RedHill Biopharma Ltd. has secured a final judgment of $10.5 million from the New York Supreme Court, allowing the company to enforce the ruling. This decision is a significant legal victory for RedHill, potentially impacting its financial position and operational capabilities moving forward. The $10.5 million judgment is likely to significantly enhance RedHill's financial resources and operational flexibility.

RedHill Biopharma Ltd. received a notification from Nasdaq indicating that it no longer meets the minimum bid price requirement for continued listing on the exchange. The company has a 180-day grace period to regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. RedHill plans to monitor its stock price and may consider options to address the situation, including a potential reverse stock split. The notification from Nasdaq could moderately influence investor sentiment and stock performance, but the company has time to address the issue.

RedHill Biopharma Ltd. has secured a $4 million strategic investment and entered into a co-commercialization partnership for its product Talicia®. This deal aims to enhance the market presence and distribution of Talicia®, which is used for treating H. pylori infections. The partnership is expected to provide additional resources and support for the product's growth in the U.S. market. The strategic investment and co-commercialization partnership are significant moves that could enhance Talicia®'s market position and financial performance.

Cumberland Pharmaceuticals has announced the addition of an established FDA-approved product to its commercial portfolio, enhancing its offerings and potentially expanding its market reach. The addition of an FDA-approved product may moderately influence financial performance and competitive positioning.

RedHill Biopharma Ltd. has signed a new deal worth over $1.8 million in sales royalties for its product Talicia® in the Middle East. This agreement is expected to enhance the company's revenue stream and expand its market presence in the region, reflecting a strategic move to capitalize on the growing demand for its offerings. The new sales royalties deal is likely to significantly impact RedHill Biopharma's future revenue and market positioning in the Middle East.

RedHill Biopharma Ltd. has successfully won an appeal in the New York Supreme Court, which upholds a $10 million summary judgment against Kukbo. This ruling reinforces RedHill's legal position and may have significant implications for its financial standing and operations. The court ruling is likely to have a significant impact on RedHill's financial performance and investor sentiment.

RedHill Biopharma Ltd. reported its financial results for the first half of 2025, highlighting key operational achievements and financial metrics. The company continues to advance its pipeline and strategic initiatives, aiming to enhance its market position and shareholder value. Specific figures regarding revenue, expenses, and product development milestones were disclosed, reflecting the company's ongoing efforts in the biopharmaceutical sector. The financial results and operational highlights indicate moderate progress that may influence future performance but are balanced by existing market conditions.

RedHill Biopharma Ltd. has been awarded $1.8 million in legal costs and expenses by the New York Supreme Court, in addition to a prior summary judgment win of $8.25 million. This ruling is part of ongoing legal proceedings involving the company. The legal victory and awarded costs may positively influence RedHill's financial performance and market sentiment, but the overall impact is expected to be limited.

RedHill Biopharma Ltd. has received licensing payments totaling $1.1 million for its product Talicia®. This payment is part of the company's ongoing efforts to monetize its assets and enhance its financial position. The funds will support RedHill's strategic initiatives and operational activities. The licensing payments provide a moderate boost to financial performance but do not fundamentally change the company's trajectory.

RedHill Biopharma Ltd. received positive FDA feedback for its RHB-204 Crohn's disease program, allowing for a novel Phase 2 study targeting Mycobacterium avium subspecies paratuberculosis (MAP)-positive patients. This groundbreaking approach aims to address both the cause and symptoms of Crohn's disease. Collaborations with academic centers for advanced MAP detection diagnostics have been initiated, overcoming previous barriers. The study's innovative design is expected to reduce sample size and costs. RHB-204, a next-generation formulation of RHB-104, is patent protected until 2041 and shows promise based on previous Phase 3 results. The Crohn's disease market is projected to grow significantly, enhancing the commercial potential for new therapies. Positive FDA feedback and innovative study design could significantly impact RedHill's future performance and market positioning.

RedHill Biopharma Ltd. has initiated recruitment for an expanded Phase 2 study evaluating the combination of opaganib and darolutamide in patients with advanced prostate cancer. This study aims to assess the safety and efficacy of the drug combination, building on previous findings that suggest potential benefits in treating this patient population. The company is focused on advancing its oncology pipeline and addressing unmet medical needs in cancer treatment. The initiation of this expanded study represents a significant strategic move that could enhance RedHill's position in the oncology market.

RedHill Biopharma Ltd. has successfully secured an asset freeze against Kukbo following a New York Supreme Court summary judgment win, which includes $8.25 million in damages plus legal fees. This ruling is a significant legal victory for RedHill, potentially impacting its financial standing and operations. The legal victory and asset freeze could significantly enhance RedHill's financial position and operational stability.